Vasoactive effect of sera from preeclamptic patients

Area of Science:

• Obstetrics and Gynecology
• Vascular Physiology
• Biomedical Science

Background:

• Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage.
• The underlying mechanisms of preeclampsia, particularly its vasoactive components, require further elucidation.

Purpose of the Study:

• To develop and validate a bioassay for measuring serum vasoactivity in preeclamptic patients.
• To investigate the effect of magnesium sulfate (MgSO4) treatment on serum vasoactivity.

Main Methods:

• Intravital microscopy was employed to assess changes in mouse mesenteric arteriole and venule diameters.
• A vasoactive index (VI) was calculated based on pre- and post-serum injection measurements.
• Sera from preeclamptic patients (untreated and MgSO4-treated), normal primigravid patients, and saline controls were used.

Main Results:

• Serum from untreated preeclamptic patients significantly reduced arteriole diameter (VIa = 0.64), indicating potent vasoactivity.
• This vasoactivity was significantly higher in patients with antepartum onset compared to intrapartum onset.
• Serum from MgSO4-treated preeclamptic patients showed no significant difference in VIa compared to normal controls (VIa = 0.91).

Conclusions:

• A vasoactive substance in preeclamptic serum contributes to arteriolar vasospasm.
• The magnitude of this vasoactivity correlates with preeclampsia duration and severity.
• Magnesium sulfate treatment effectively masks or eliminates this serum-induced vasoactivity.